Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies

Infection and Immunity

Volumn 66, Issue 11, 1998, Pages 5372-5378

  Amura, Claudia R ^a,c   Silverstein, R ^a   Morrison, D C ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; THIOGLYCOLIC ACID;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; HOST RESISTANCE; IMMUNE RESPONSE; IN VITRO STUDY; MACROPHAGE ACTIVATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SENSITIZATION; SEPSIS; THROMBOCYTE ACTIVATION;

EID: 0032410806     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.11.5372-5378.1998     Document Type: Article

References (13)

1. Abraham, E., R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, R. Balk, R. Allred, et al. 1997. Efficacy and safety of monoclonal antibodies to tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha Mab sepsis group. JAMA 273:93-4-941.
2. Amura, C. R., L. C. Chen, N. Hirohashi, M. G. Lei, and D. C. Morrison. 1997. Two functionally independent pathways for the LPS-dependent activation of mouse peritoneal macrophages. J. Immunol. 159:5079-5083.
3. Amura, C. R., P. A. Fontan, N. Sanjuan, and D. O. Sordelli. 1994. The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model. Clin. Immunol. Immunopathol. 73:261-266.
4. Beutler, B., I. W. Milsark, and A. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 229:869-871.
5. Bone, R. C. 1991. Sepsis syndrome. New insights into its pathogenesis and treatment. Infect. Dis. Clin. N. Am. 5:793-805.
6. Bucklin, S. E., S. W. Russell, and D. C. Morrison. 1994. Participation of IFN-gamma in the pathogenesis of LPS lethality. Prog. Clin. Biol. Res. 388:399-406.
7. Cannon, J. G. 1992. Endotoxin and cytokine responses in human volunteers, p. 312-326. In J. L. Ryan and D. C. Morrison (ed.), Bacterial endotoxic lipopolysaccharides. CRC Press, Inc., Boca Raton, Fia.
8. Echtenacher, B., L. Hültner, and D. N. Männel. 1996. Cellular and molecular mechanisms of TNF protection in septic peritonitis. J. Inflamm. 47:85-89.
9. Eskandari, M. K., G. Bolgos, C. Miller, D. T. Nguyen, L. E. DeForge, and D. G. Remick. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724-2730.
10. Fiedler, V. B., I. Loof, E. Sander, V. Voehringer, C. Galanos, and M. A. Fournel. 1992. Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J. Lab. Clin. Med. 120:574-588.
11. Franks, A. K., K. I. Kujawa, and L. J. Yaffe. 1991. Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect. Immun. 59:2609-2614.
12. Freudenberg, M. A., and C. Galanos. 1991. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59:2110-2115.
13. Freudenberg, M. A., D. Keppler, and C. Galanos. 1986. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect. Immun. 51:891-895.